Evidence map›Paper›PMID 40750708›Full record

ArticleExperimental & molecular medicine2025

METTL1-driven epitranscriptomic enhancement of TXNDC12 boosts c-Myc stability through USP5 in HNSCC.

Zizhao Mai, Jiarong Zheng, Ye Lu, Pei Lin, Yunfan Lin, Yucheng Zheng, Xu Chen, Bing Guo, Li Cui, Xinyuan Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. The emerging roles of METTL1-mediated tRNA mFrontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zizhao Mai *Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China.
Jiarong Zheng *Department of Dentistry, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Ye LuStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China.
Pei LinStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China.
Yunfan LinStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China.
Yucheng ZhengStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China.
Xu ChenStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China.
Bing GuoDepartment of Dentistry, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Li CuiStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China. licui@smu.edu.cn.ORCID http://orcid.org/0000-0001-9814-6945
Xinyuan ZhaoStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China. zhaoxinyuan1989@smu.edu.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81901006National Natural Science Foundation of China (National Science Foundation of China) 82372905
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignancy worldwide. Advancing understanding of the molecular mechanisms driving tumor progression and resistance to therapy is essential for developing new strategies to improve patient outcomes in HNSCC. Here we demonstrate that elevated expression of thioredoxin domain-containing protein 12 (TXNDC12) in HNSCC is associated with adverse clinical outcomes and reduced survival. Modulating TXNDC12 levels demonstrates that its reduction curtails aggressive tumor phenotypes and cisplatin resistance, while its overexpression exacerbates these characteristics. Comprehensive RNA transcriptomic analysis reveals that depletion of TXNDC12 leads to significant suppression of c-Myc signaling pathways. Mechanistically, TXNDC12 stabilizes c-Myc protein by promoting its interaction with USP5, thus preventing proteasomal degradation of c-Myc. Moreover, METTL1 enhances TXNDC12 mRNA stability via an m

Indexed as

Epigenesis, GeneticHead and Neck NeoplasmsMethyltransferasesProto-Oncogene Proteins c-mycSquamous Cell Carcinoma of Head and NeckTranscriptomeUbiquitin-Specific ProteasesAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceProtein StabilityRNA StabilitySignal TransductionMethyltransferasesMYC protein, humanProto-Oncogene Proteins c-mycUbiquitin-Specific Proteases

Identifiers

PMID40750708
PMCPMC12411639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.